Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
82 hedge funds and large institutions have $30.5M invested in Oncternal Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 12 closing their positions.
89% more call options, than puts
Call options by funds: $223K | Put options by funds: $118K
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
8% more funds holding
Funds holding: 76 → 82 (+6)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
46% less capital invested
Capital invested by funds: $56.8M → $30.5M (-$26.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$786K |
| 2 |
Morgan Stanley
New York
|
+$335K |
| 3 |
Millennium Management
New York
|
+$301K |
| 4 |
Goldman Sachs
New York
|
+$212K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.07M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$686K |
| 3 |
Norges Bank
Oslo,
Norway
|
-$674K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$580K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$555K |
ONCT Hedge Fund Activity: Q4 2021 in Review
82 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2021, worth a combined $30.5M — down 46% from $56.8M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ONCT positions and 12 closed out — a net gain of 6 holders — while 22 added to existing stakes and 25 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $786K. The largest seller was Two Sigma Investments, cutting an estimated $1.07M.
- 82 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2021, up from 76 in Q3 2021.
- Funds reported $30.5M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2021, down 46% quarter-over-quarter.
- 18 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2021 and 12 closed out, a net change of +6 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2021 was Renaissance Technologies, an estimated $786K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2021 was Two Sigma Investments, an estimated $1.07M sold.
Based on aggregated 13F filings for Q4 2021.